Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
54
GDERF Quote, Financials, Valuation and Earnings
Last price:
$195.75
Seasonality move
:
0%
Day range:
$195.75 - $195.75
52-week range:
$97.00 - $195.75
Dividend yield:
0.04%
P/E ratio:
123.14x
P/S ratio:
10.00x
P/B ratio:
4.86x
Volume:
2.3K
Avg. volume:
1.5K
1-year change:
101.8%
Market cap:
$46B
Revenue:
$4.4B
EPS (TTM):
$1.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GDERF
Galderma Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.17% | -6.14% | $9.61 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 30.35% | -70.04% | $401.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GDERF
Galderma Group AG
|
$195.75 | -- | $46B | 123.14x | $0.07 | 0.04% | 10.00x |
|
ACIU
AC Immune SA
|
$2.80 | $9.61 | $281.7M | -- | $0.00 | 0% | 54.60x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.77 | $30.00 | $9.6M | 0.77x | $0.00 | 0% | 35.54x |
|
CRSP
CRISPR Therapeutics AG
|
$56.88 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.74x |
|
ONC
BeOne Medicines Ltd.
|
$322.90 | $401.52 | $35.7B | 621.32x | $0.00 | 0% | 7.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GDERF
Galderma Group AG
|
26.02% | 1.717 | -- | 0.80x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GDERF
Galderma Group AG
|
-- | -- | 3.62% | 4.9% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Galderma Group AG vs. Competitors
-
Which has Higher Returns GDERF or ACIU?
AC Immune SA has a net margin of -- compared to Galderma Group AG's net margin of -1688.87%. Galderma Group AG's return on equity of 4.9% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital GDERFGalderma Group AG-- -- $10.4B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About GDERF or ACIU?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.61 which suggests that it could grow by 244.63%. Given that AC Immune SA has higher upside potential than Galderma Group AG, analysts believe AC Immune SA is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GDERFGalderma Group AG0 0 0 ACIUAC Immune SA3 0 0 -
Is GDERF or ACIU More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock GDERF or ACIU?
Galderma Group AG has a quarterly dividend of $0.07 per share corresponding to a yield of 0.04%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays 17.51% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Galderma Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GDERF or ACIU?
Galderma Group AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Galderma Group AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Galderma Group AG's price-to-earnings ratio is 123.14x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 10.00x versus 54.60x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDERFGalderma Group AG10.00x 123.14x -- -- ACIUAC Immune SA54.60x -- $1.2M -$19.8M
-
Which has Higher Returns GDERF or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Galderma Group AG's net margin of -3178.71%. Galderma Group AG's return on equity of 4.9% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital GDERFGalderma Group AG-- -- $10.4B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About GDERF or ADXN?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 286.1%. Given that Addex Therapeutics Ltd. has higher upside potential than Galderma Group AG, analysts believe Addex Therapeutics Ltd. is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GDERFGalderma Group AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is GDERF or ADXN More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock GDERF or ADXN?
Galderma Group AG has a quarterly dividend of $0.07 per share corresponding to a yield of 0.04%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays 17.51% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend. Galderma Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GDERF or ADXN?
Galderma Group AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Galderma Group AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Galderma Group AG's price-to-earnings ratio is 123.14x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 10.00x versus 35.54x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDERFGalderma Group AG10.00x 123.14x -- -- ADXNAddex Therapeutics Ltd.35.54x 0.77x $62K -$2M
-
Which has Higher Returns GDERF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Galderma Group AG's net margin of -11973.12%. Galderma Group AG's return on equity of 4.9% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital GDERFGalderma Group AG-- -- $10.4B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About GDERF or CRSP?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 42.99%. Given that CRISPR Therapeutics AG has higher upside potential than Galderma Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GDERFGalderma Group AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is GDERF or CRSP More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock GDERF or CRSP?
Galderma Group AG has a quarterly dividend of $0.07 per share corresponding to a yield of 0.04%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays 17.51% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Galderma Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GDERF or CRSP?
Galderma Group AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Galderma Group AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Galderma Group AG's price-to-earnings ratio is 123.14x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 10.00x versus 129.74x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDERFGalderma Group AG10.00x 123.14x -- -- CRSPCRISPR Therapeutics AG129.74x -- $889K -$106.4M
-
Which has Higher Returns GDERF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Galderma Group AG's net margin of 8.84%. Galderma Group AG's return on equity of 4.9% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital GDERFGalderma Group AG-- -- $10.4B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About GDERF or ONC?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 24.35%. Given that BeOne Medicines Ltd. has higher upside potential than Galderma Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GDERFGalderma Group AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is GDERF or ONC More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock GDERF or ONC?
Galderma Group AG has a quarterly dividend of $0.07 per share corresponding to a yield of 0.04%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays 17.51% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Galderma Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GDERF or ONC?
Galderma Group AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Galderma Group AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Galderma Group AG's price-to-earnings ratio is 123.14x while BeOne Medicines Ltd.'s PE ratio is 621.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 10.00x versus 7.21x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GDERFGalderma Group AG10.00x 123.14x -- -- ONCBeOne Medicines Ltd.7.21x 621.32x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
